ELV · Healthcare

Elevance Health, Inc.

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

News · 2026-08-08

• Revenue Performance and MixImportance 21 · Surprise 6
  Elevance Health reported quarterly revenue of $49.83 billion. The reported revenue exceeded the materiality threshold of $1.514 billion. The digest does not provide a year-over-year or sequential revenue comparison or…
• Capital Return ProgramImportance 13 · Surprise 6
  Elevance Health declared a quarterly dividend of $1.72 per share. The dividend declaration represents a direct capital return to shareholders. The digest does not state the payment date, record date, aggregate payout,…

News · 2026-08-07

• Revenue Performance and MixImportance 21 · Surprise 6
  Elevance Health reported quarterly revenue of $49.83 billion. The reported revenue exceeded the materiality threshold of $1.514 billion. The digest does not provide a year-over-year or sequential revenue comparison or…
• Capital Return ProgramImportance 13 · Surprise 6
  Elevance Health declared a quarterly dividend of $1.72 per share. The dividend declaration represents a direct capital return to shareholders. The digest does not state the payment date, record date, aggregate payout,…

News · 2026-08-06

• Revenue Performance and MixImportance 21 · Surprise 6
  Elevance Health reported quarterly revenue of $49.83 billion. The reported revenue exceeded the materiality threshold of $1.514 billion. The digest does not provide a year-over-year or sequential revenue comparison or…

News · 2026-08-05

• Revenue Performance and MixImportance 21 · Surprise 6
  Elevance Health reported quarterly revenue of $49.83 billion. The reported revenue exceeded the materiality threshold of $1.514 billion. The digest does not provide a year-over-year or sequential revenue comparison or…

News · 2026-08-04

• Revenue Performance and MixImportance 21 · Surprise 6
  Elevance Health reported quarterly revenue of $49.83 billion. The reported revenue exceeded the materiality threshold of $1.514 billion. The digest does not provide a year-over-year or sequential revenue comparison or…
• Capital Return ProgramImportance 13 · Surprise 6
  Elevance Health declared a quarterly dividend of $1.72 per share. The dividend declaration represents a direct capital return to shareholders. The digest does not state the payment date, record date, aggregate payout,…

10-Q · 2026-07-15

• Medicare Risk Adjustment / RADVImportance 72 · Surprise 74
  Elevance notes CMS plans to substantially increase the scale and pace of Risk Adjustment Data Validation (RADV) audits (announced May 2025) and warns that changes to risk-adjustment auditing could increase financial…
• Operating Gain DeclineImportance 70 · Surprise 56
  Total operating gain decreased materially — down 27.3% for the three months and 31.2% for the six months ended June 30, 2026 — with total operating gain of $1,763 million (three months) and $3,849 million (six months).…
• IRA Drug & Subsidy ImpactsImportance 69 · Surprise 76
  The Inflation Reduction Act (IRA) of 2022 contains drug pricing and tax provisions (including limited Medicare drug price negotiation beginning in 2026, Medicare Part D redesign, inflation-based manufacturer rebates,…
• Membership / Enrollment TrendsImportance 68 · Surprise 58
  Total medical membership declined 1.5% from June 30, 2025 to June 30, 2026, driven primarily by Medicaid attrition (8,358k vs 8,733k, down 375k or 4.3%) and declines in Medicare lines. Medicare Advantage membership…
• OBBBA Federal ChangesImportance 65 · Surprise 60
  The One Big Beautiful Bill Act (OBBBA), signed July 4, 2025, contains multiple provisions affecting Medicaid reverifications, work/community engagement requirements for ACA Medicaid expansion populations, changes to…
• CarelonRx Outsourcing and Volume/Cost TrendsImportance 64 · Surprise 42
  CarelonRx provides comprehensive pharmacy services (home delivery, specialty, claims adjudication, formulary management, infusion/injectable therapies) to affiliated and unaffiliated customers and delegates certain…
• Operating Cash Flow TrendsImportance 63 · Surprise 64
  Operating cash flow (net cash provided by operating activities) improved to $6,245 million for the six months ended June 30, 2026, from $3,071 million for the six months ended June 30, 2025, an increase of $3,174…
• Transformation ProgramImportance 63 · Surprise 70
  In Q1 2026 Elevance initiated a 2026–2027 Operating Model Transformation Program to streamline decision-making, simplify organizational structures, modernize IT platforms and increase use of advanced technologies,…
• Medicare Advantage Risk Adjustment ContingencyImportance 59 · Surprise 60
  The Company recorded a loss contingency accrual in the six months ended June 30, 2026 for the best estimate of identified potential exposure related to the resubmission of certain historical Medicare Advantage risk…
• Accrued Legal and RegulatoryImportance 59 · Surprise 42
  Management attributes the primary driver of the six‑month net income decline to a loss contingency accrual for the company's best estimate of potential exposure related to the resubmission of certain historical…
• PBM Reform LegislationImportance 59 · Surprise 60
  The Consolidated Appropriations Act of 2026 (enacted February 2026) includes pharmacy benefit manager (PBM) reforms that require PBMs to remit all rebates, fees (other than bona fide service fees) and other…
• Mental Health Parity RegulationsImportance 56 · Surprise 42
  The Tri-Agencies issued final mental health parity regulations in September 2024 that require health plans to make administrative and operational changes to comply; some provisions became effective January 1, 2025.…
• Liquidity and Cash PositionImportance 54 · Surprise 14
  Elevance reported consolidated cash, cash equivalents and investments in fixed maturity and equity securities of $38,773 at June 30, 2026, an increase of $1,537 since December 31, 2025, driven primarily by increased…
• Operating Expense TrendsImportance 52 · Surprise 42
  Operating expense increased meaningfully in the periods presented, driven by targeted investments to support workforce and technology adoption, increased expenses to address regulatory matters and higher premium tax…
• Regulatory Capital and Dividend RestrictionsImportance 52 · Surprise 42
  Many Elevance subsidiaries are subject to state insurance regulation that can restrict the timing and amount of dividends and other distributions to parent companies, and statutory (regulatory) accounting practices…
• Shareholders' Net Income and EPS DeclineImportance 50 · Surprise 58
  Shareholders’ net income was $3,227 million for the six months ended June 30, 2026, a decrease of $699 million, or 17.8%, from $3,926 million for the six months ended June 30, 2025. Fully-diluted EPS declined to $14.73…
• Medical Cost TrendsImportance 50 · Surprise 24
  Elevance cites elevated medical cost trends driven by utilization and unit cost increases across provider types, with specific pressure from specialty pharmaceuticals and new indications for existing drugs. The company…
• Outstanding Indebtedness and RatingsImportance 48 · Surprise 14
  Elevance reports and monitors its consolidated debt-to-capital ratio as a key leverage metric; the ratio was 40.8% at June 30, 2026 compared with 42.1% at December 31, 2025. The company issues long-term Notes…
• Interest Rate and Refinancing ExposureImportance 48 · Surprise 6
  Elevance periodically accesses capital markets and may issue long-term debt (Notes) to refinance debt, finance acquisitions or repurchase shares, and some Notes may include call or put features tied to…
• Net Losses on Financial InstrumentsImportance 45 · Surprise 64
  Net losses on financial instruments decreased to a net loss of $56 million for the three months ended June 30, 2026 from $131 million in the prior-year quarter, a 57.3% improvement. The MD&A attributes the decrease to…
• Capital Return ProgramImportance 43 · Surprise 32
  Repurchase and retirement of common stock totaled $1,358 million for the six months ended June 30, 2026, compared with $1,258 million for the six months ended June 30, 2025.,Cash dividends paid were $749 million for the six months ended June 30, 2026 compared with $771 million in the prior-year period.,At June 30, 2026, the parent company held $2,062 million of cash, cash equivalents and investments available for general corporate use, including potential future common stock repurchases and dividends.
• Liquidity Outlook and Funding SourcesImportance 43 · Surprise 6
  Management believes cash on hand, future operating cash receipts, investments and funds available under the commercial paper program, the $5,000 million 5-Year Facility and FHLB borrowings will be adequate to fund expected cash disbursements over the next twelve months.,The company had $0 outstanding commercial paper and $0 short-term FHLB borrowings at June 30, 2026, providing immediate liquidity capacity if market issuance is required.,Elevance states it expects funds from future operating cash flows, cash and investments and its 5-Year Facility or other financing sources to be sufficient for future operations, commitments and capital acquisitions.
• Capital Resources and FacilitiesImportance 43 · Surprise 6
  Elevance maintains multiple capital sources including an unlimited shelf registration statement, a $5,000 senior revolving credit facility (the 5-Year Facility) maturing in September 2030, a $5,000 authorized…
• Net Investment Income TrendsImportance 40 · Surprise 56
  Net investment income rose significantly — up 44.9% for the three months and 36.5% for the six months ended June 30, 2026 — primarily due to higher income from alternative investments partially offset by lower income…
• No Surprises IDR RegulationsImportance 40 · Surprise 42
  In May 2026 the Tri-Agencies (HHS, Labor, Treasury) issued final regulations updating the Independent Dispute Resolution (IDR) process under the No Surprises Act, primarily addressing the operations and administration…
• BCBSA Antitrust LitigationImportance 38 · Surprise 50
  Elevance is a defendant in the multi-district In re Blue Cross Blue Shield Antitrust Litigation, which challenges elements of licensing agreements between the Blue Cross Blue Shield Association (BCBSA) and the…
• Geographic Market CommentaryImportance 34 · Surprise 42
  Elevance reports expansion of its Individual Public Exchange presence: in 2025 it entered select Florida markets via Simply Healthcare and expanded in Maryland and Texas via Wellpoint, and in 2026 added Washington via…
• Marketplace Regulation ChangesImportance 34 · Surprise 42
  CMS finalized the Marketplace Integrity and Affordability Regulation in June 2025, which changes Public Exchange open enrollment periods (effective plan year 2027) and eligibility rules for Premium Tax Credits (PTCs),…
• Vision Membership GrowthImportance 30 · Surprise 40
  Vision membership increased 10.6% year-over-year to 11.9 million as of June 30, 2026, driven by higher sales into Medicaid, Employer Group and Individual health plans. Management notes the growth was partially offset…
• CarelonRx CVS AgreementImportance 26 · Surprise 24
  CarelonRx delegates certain core pharmacy services to CaremarkPCS Health, L.L.C. (a CVS subsidiary) under the CVS Agreement with a contractual term through December 31, 2027. Elevance may elect to extend CVS services…
• Pricing TrendsImportance 19 · Surprise 6
  Elevance states it prices health benefit products to reflect anticipated medical cost trends but faces timing lags and competitive pressures that can leave pricing misaligned with current underlying costs. The company…
• Regulatory Statutory Capital (RBC) ComplianceImportance 13 · Surprise 6
  Elevance’s regulated subsidiaries are subject to statutory risk-based capital (RBC) requirements based largely on the NAIC RBC Model Act in their states of domicile.,The company reported that its regulated subsidiaries’ RBC levels as of December 31, 2025 were in excess of all applicable mandatory RBC requirements.,In addition to RBC compliance, management states it is in compliance with liquidity and capital requirements for a BCBSA licensee and California tangible net worth requirements for certain subsidiaries.